{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-122244","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.357168+00:00","generated_at":"2026-05-30T04:39:52.727261+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Adicet Bio Q3 net loss $30.5M; ADI-001 trial expanded to six autoimmune indications","bullets":["Net loss of $30.5M ($0.34 per share) vs $49.9M ($1.16) in Q3 2023; cash $202.1M.","ADI-001 Phase 1 now covers LN, SLE, SSc, IIM, SPS, AAV; preliminary LN data expected 1H25.","FDA cleared IND amendment for ADI-001 in IIM and SPS in October 2024.","ADI-270 granted Fast Track for metastatic/advanced ccRCC; Phase 1 enrollment planned in Q4 2024.","Appointed Lloyd Klickstein, M.D., Ph.D. to Board of Directors in August 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-122244","json":"https://secwatch.observer/filing/0000950170-24-122244.json","markdown":"https://secwatch.observer/filing/0000950170-24-122244.md","text":"https://secwatch.observer/filing/0000950170-24-122244.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024122244/0000950170-24-122244-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024122244/acet-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:39:52.727261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}